Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ocumension Acquires China Rights to Ocular Inflammation Product in $12 Million Deal

publication date: Jan 30, 2020

Ocumension, a China ophthalmology company, announced a $12 million agreement for Greater China rights to Dexycu® 9%, a treatment for inflammation following ocular surgery, from EyePoint Pharma (NSDQ: EYPT) of Massachusetts. Dexycu® 9%, a sustained release product, can provide a benefit for up to 22 days following cataract surgery. Ocumension will pay $2 million upfront and also make up to $10 million in milestone payments, plus royalties. Ocumension was established by 6 Dimensions Capital in 2018 to in-license ophthalmology products for China use. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here